Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Age 18-65~* Morning serum testosterone (T) \<300 ng/dL on two occasions~Exclusion Criteria:~* Significant intercurrent disease~* Abnormal prostate digital rectal exam, elevated PSA, AUA symptom score \>15 or history of prostate cancer.~* Serum transaminases \>2 times upper limit of normal~* Serum bilirubin \>2.0 mg/dL~* Hematocrit \<35% or \>50%~* BMI \>36~* Untreated, obstructive sleep apnea.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fasting (Treatment A) (Type: EXPERIMENTAL): Single dose of oral testosterone undecanoate (containing 300 mg T) administered orally in a fasted state
- Very low fat diet (Treatment B) (Type: EXPERIMENTAL): Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of \~800 calories with very low fat (6-10% fat).
- Low fat diet (Treatment C) (Type: EXPERIMENTAL): Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of \~800 calories with low fat (20% fat).
- Normal diet (Treatment D) (Type: EXPERIMENTAL): Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of \~800 calories with normal fat (30% fat).
- High fat diet (Treatment E) (Type: EXPERIMENTAL): Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of \~800 calories with high fat (50% fat).

Based on this trial design, predict the completion outcome and termination type (if applicable).